180300-90-7

Upstream product

• 6022-96-4 5-O-benzoyl-α-D-xylofuranose 
• 98-88-4 benzoyl chloride 
• 20031-21-4 1,2-O-isopropylidene-α-D-xylose 
• 6698-46-0 5-O-benzoyl-1,2-O-isopropylidene-α-D-ribofuranos-3-ulose 
• 1826-67-1 vinyl magnesium bromide 
• 180300-89-4 5-O-tert-butyldimethylsilyl-1,2-O-isopropylidene-3-C-ethenyl-α-D-ribofuranose 
• 103931-45-9 5-O-(tert-butyldimethylsilyl)-1,2-O-isopropylidene-α-D-erythro-pentofuranos-3-ulose 

Downstream Products

• 180300-67-8 1-(2,3,5-tri-O-benzoyl-3-C-ethenyl-β-D-ribofuranosyl)uracil 
• 180300-61-2 1-(2,3,5-tri-O-benzoyl-3-C-ethenyl-β-D-ribofuranosyl)cytosine 

Relevant academic research and scientific papers

SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5

The disclosure is directed to methods of treating disease using compounds of Formula (I).

Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)

The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

Nucleosides and nucleotides, 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3- C-ethynyl-β-d-ribo-pentofuranosyl)cytosine and -uracil

We previously designed 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)uracil (EUrd) and its cytosine congener (ECyd) as potential multifunctional antitumor nucleoside antimetabolites. They showed potent and broad-spectrum antitumor activity against various human

3'-substituted nucleoside derivatives

The invention relates to a 3'-substituted nucleoside derivative represented by the following general formula (1): STR1 wherein B means a nucleic acid base which may have a substituent, Z represents a lower alkynyl or lower alkenyl group which may be subst